AI Support Tool Demonstrates Detection Utility for Melanoma at Primary Care Practices
Source: OncLive, May 2024
An artificial intelligence-based smartphone app used by primary care physicians showed high diagnostic accuracy in detecting cutaneous melanoma.
Dermalyser, an artificial intelligence (AI)-based clinical decision support tool, displayed high diagnostic accuracy in detecting cutaneous melanoma in a primary care setting, according to findings from a prospective clinical study (NCT05172232) published in the British Journal of Dermatology.
The tool, a smartphone app that uses AI to analyze dermoscopic images taken by a primary care physician, showed an area under the receiver operating characteristic (AUROC) curve of 0.960 (95% CI, 0.928-0.980), corresponding to a maximum sensitivity and specificity of 95.2% and 84.5%, respectively, in identifying melanomas. Additionally, in invasive melanoma only, the AUROC was 0.988 (95% CI, 0.965-0.997) with a maximum sensitivity of 100% and a maximum specificity of 92.6%. Of 253 lesions analyzed, 21 proved to be melanoma including 11 thin invasive melanomas and 10 melanomas in situ.